Video

New guidelines for gadolinium-based contrast agents take conservative stance


 

REPORTING FROM THE CMSC ANNUAL MEETING


Dr. Li concurred.

“It remains indispensable in patients presenting with their first clinical attack (CIS) as [its] use allows for an earlier diagnosis by demonstrating lesion dissemination in time in addition to lesion dissemination in space, the hallmarks for the diagnosis of MS. Early diagnosis leads to early treatment, which may help in preventing disease progression and improve long-term prognosis.”

Dr. Li has received multiple drug company grants and acted as a consultant to multiple pharmaceutical companies, but had no disclosures relevant to gadolinium.

Pages

Recommended Reading

Genetic Variations in the CYP2J2 Region May Be Associated With MS Risk
MDedge Neurology
Pediatric MS gets a win with fingolimod
MDedge Neurology
Can Neurologists Predict a Patient’s Nonadherence to DMTs for MS?
MDedge Neurology
Research on exercise in MS needs to build up some muscle
MDedge Neurology
Value of alemtuzumab demonstrated in RRMS patients with prior IFNB-1a treatment
MDedge Neurology
Rapid Foot-Tapping Task Distinguishes Between MS Subtypes
MDedge Neurology
Oligoclonal Bands May Predict MS Relapses and Progression
MDedge Neurology
A Mediterranean Diet May Be Associated With Lower Depression and Cognitive Impairment Scores in Patients With MS
MDedge Neurology
How Does the Gut Microbiome Differ in Patients With Relapsing MS Versus Controls?
MDedge Neurology
VIDEO: PML prevention is possible, even when treating patients with aggressive MS
MDedge Neurology